Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab, Temozolomide, and Erlotinib in Newly Diagnosed Glioblastoma or Gliosarcoma
NCT00525525Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Sep 2007
- Primary completion
- May 2013
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, erlotinib in glioblastoma (GBM), Gliosarcoma (GS), sponsored by University of California, San Francisco. Started Sep 2007; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00525525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00525525.